20 / 33
Stromal PD-L1 modulation of T cells
Immune cell modulation of T
cells
PD-L1/PD-1-mediated inhibition
of
tumor cell killing
IFN
γ
-mediated
upregulation of tumor
PD-L1
Priming and activation of
T cells
PD-L2-mediated inhibition of TH
2
T cells
receptor
B7.1
Chen DS, Irving BA, Hodi FS.
Clin Cancer Res.
2012;18:6580.
As Good as Immunotherapy is… it only works this well for about 20-30%
of patients: So what about the other 80% of patients?
Multiple Factors Determine Sensitivity and Resistance in the Immune Microenvironment
Potential for benefit in all
cancers!